Pilot Study of FOLFOX6 Plus Sir-Spheres® Microspheres (Chemo-Radiotherapy) in Combination With Bevacizumab (Avastin) as a First Line Treatment in Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Toxicity and safety
from study entry until 28 days after last cycle of chemotherapy
Yes
Dennis Carter, MD
Principal Investigator
Rocky Mountain Cancer Center
United States: Food and Drug Administration
STX0207
NCT00735241
July 2008
March 2009
Name | Location |
---|---|
William Beaumont Hospital | Royal Oak, Michigan 48073 |
Carolinas Medical Center | Charlotte, North Carolina 28232-2861 |
Sacred Heart Medical Center | Spokane, Washington 99204 |